Scientific article
Review
English

Fibrinogen concentrates in hereditary fibrinogen disorders: past, present and future

Published inHaemophilia
Publication date2019
Abstract

Hereditary fibrinogen disorders (HFD) are rare coagulation disorders. Even if the spectrum of symptoms is broad depending on the sub-type, bleeding is the most common complication. Of the available sources of fibrinogen replacement, fibrinogen concentrate provides a safer and more effective option to treat and prevent bleeding. Recent clinical trials on established and new fibrinogen concentrates have increased our knowledge on the clinical pharmacology of these products, pointing out possible age and weight differences for dose adjustment. The efficacy of fibrinogen infusions has been demonstrated, especially for the management of acute bleeding with an excellent response based on investigator rating. The target fibrinogen levels in the setting of both minor and major surgeries have been better specified. The safety has been confirmed with a low number of adverse events but there still remains concern over possible thrombotic risks. Pharmacological, clinical aspects and future perspectives on the utilization of fibrinogen concentrates in the treatment and prevention of bleeding in patients with HFD are reviewed.

Citation (ISO format)
CASINI, Alessandro, DE MOERLOOSE, Philippe. Fibrinogen concentrates in hereditary fibrinogen disorders: past, present and future. In: Haemophilia, 2019. doi: 10.1111/hae.13876
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1351-8216
259views
0downloads

Technical informations

Creation12/14/2019 11:49:00 AM
First validation12/14/2019 11:49:00 AM
Update time05/03/2024 4:52:08 PM
Status update05/03/2024 4:52:08 PM
Last indexation10/31/2024 5:15:03 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack